A recent Politico article outlined the looming agenda facing Congress as 2018 begins: Fund the government, raise the debt ceiling, modify spending caps, address healthcare subsidies, allocate additional funds for disaster relief, and address the status of millions of undocumented young immigrants.1 Amid all that activity, the ACR, through its Government Affairs Committee (GAC) and…
Protect Your Patients’ Access to Care & Treatment
Persistent Challenges Sometimes the challenges seem neverending. In addition to the rigors of our daily lives as rheumatology health professionals—growing administrative burdens, increasing pressures to fund research and achieve balance in family and personal lives—we face a growing number of challenges related to the rapidly escalating prices of rheumatology treatments. Even more unfortunately, these costs…
Year in Review: The ACR/ARHP/RheumPAC’s Advocacy Efforts in 2017
In 2017, did you interact with the Medicare payment system, receive payment for a consultation code or worry about the Centers for Medicare & Medicaid Services (CMS) reducing reimbursement through its proposed Part B Demonstration Project? If your answer to any of those questions is yes, then you directly benefited from the ACR/ARHP’s advocacy efforts….
Doctors & Political Advocacy: Tips to Get You Started
SAN DIEGO—Doctors vote less frequently than other professionals, even than farmers, reported Sen. Tim Hutchinson, who is the ACR’s lead lobbyist inside the Beltway, during an Introduction to Advocacy workshop at the 2017 ACR/ARHP Annual Meeting Nov. 3–8.1 Sen. Hutchinson, who represented Arkansas in the U.S. Senate from 1997–2003 and is now a senior director…
The American College of Rheumatology’s Legislative Successes of 2017
SAN DIEGO—The 2017 ACR/ARHP Annual Meeting, Nov. 3–8, presented opportunities to highlight its 2017 legislative advocacy victories, some of which were resolved just weeks before the conference began, as well as issues that are still outstanding. In the session, Legislative & Regulatory Update 2017, Angus Worthing, MD, chair of the ACR’s Government Advocacy Committee and…
The ACR Lobbies Against New Part B Drug Cost Adjustment Rule
The ACR and a number of other physician medical associations are lobbying for an immediate legislative fix to a piece of the MACRA law that factors high-cost Part B drugs into a rheumatology practice’s Medicare reimbursement rate through the Merit-Based Incentive Payment System (MIPS). This change, which goes into effect immediately, will impact practices in…
The ARHP Helps Rheumatology Professionals Avoid Information Overload
In a world where some information is good, more information is better and information overload is a way of life, Carole Dodge, BS, OTR, CHT—a practicing occupational therapist at the University of Michigan—considers the ARHP her professional block and tackle. “ARHP helps me sift through a lot of information and get it to a digestible…
ARHP Stands Up for Members and Patients
Editor’s note: The new Pillar Talk column is developed by the ARHP Executive Committee in an effort to share information about ongoing activities related to our four pillars: Education, Practice, Research and Advocacy. ARHP volunteers are actively involved in the ACR’s efforts to advocate for the care of our patients and the rheumatology professionals who…
RheumPAC: Answers to FAQs
What is RheumPAC? RheumPAC is the ACR’s nonpartisan political action committee (PAC) that works to elect and support pro-rheumatology candidates. It is the only PAC dedicated to the interests of the rheumatology profession. RheumPAC was created 10 years ago with the mission of educating, electing and supporting federal lawmakers who understand and can positively address…
Drug Industry on Tenterhooks as Maryland Price-Gouging Law Nears
(Reuters)—As U.S. consumer outrage grows over prescription drug prices, state authorities and patient advocates in Maryland are preparing to enforce the nation’s first law designed to punish drugmaker price-gouging. The Maryland Attorney General’s office said it will field complaints and investigate “unconscionable increases” in essential generic medicines when the closely watched law takes effect Oct….
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 20
- Next Page »